vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1462Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWОБЗОР БЕЗОПАСНОСТИ И ПЕРЕНОСИМОСТИ ОМАЛИЗУМАБАREVIEW OF SAFETY AND TOLERANCE OF OMALIZUMABЕмельяновА.В.Emel'yanovA.V.Санкт-Петербургская медицинская академия последипломного образованияРоссияSt-Petersburg Medical Academy of Postgraduate EducationRussian Federation20080511201575Вопросы современной педиатрии8790Copyright © Емельянов А., 20082008Емельянов А.Emel'yanov A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1462ReferencesDjukanovich R., Wilson S.J., Kraft M. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004; 170 (6): 583–593.Djukanovich R., Wilson S.J., Kraft M. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004; 170 (6): 583–593.Global Initiative for Аsthma. NHLB/WHO Workshop Report. 2007. 103 с.Global Initiative for Аsthma. NHLB/WHO Workshop Report. 2007. 103 с.Walker S., Monteil M., Phelan K. et al. Anti–IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; 2: CD003559.Walker S., Monteil M., Phelan K. et al. Anti–IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; 2: CD003559.Deniz Y.M., Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin. Rev. Allergy Immunol. 2005; 29 (1): 31–48.Deniz Y.M., Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin. Rev. Allergy Immunol. 2005; 29 (1): 31–48.Cox L., Platt-Mills T., Finegold I. et al. American Academy of Allergy Asthma Immunology/American College of Asthma, Allergy and Immunology Join Task Report on omalizumab associate anaphylaxis. J. Allergy Clin. Immunol. 2007; 120 (7): 1373–1377Cox L., Platt-Mills T., Finegold I. et al. American Academy of Allergy Asthma Immunology/American College of Asthma, Allergy and Immunology Join Task Report on omalizumab associate anaphylaxis. J. Allergy Clin. Immunol. 2007; 120 (7): 1373–1377Giavina-Banchi P., Giavina-Banchi M., Agondi R. et al. Omalizumab and Churg–Strauss syndrome. J. Allergy Clin. Immunol. 2008; 122 (1): 217.Giavina-Banchi P., Giavina-Banchi M., Agondi R. et al. Omalizumab and Churg–Strauss syndrome. J. Allergy Clin. Immunol. 2008; 122 (1): 217.
The authors declare that there are no conflicts of interest present.